3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
3
Status
Recruiting
3
Sponsor Class
INDUSTRY
3
Study Type
Interventional
3
Sponsor
Cancer Type
Gastrointestinal
2
Thoracic
1
Conditions
Breast Neoplasms
5
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Lung Neoplasms
3
Esophageal Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Solid Tumor, Adult
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Melanoma
1
Head and Neck Neoplasms
1
Gastrointestinal Neoplasms
1
Endometrial Neoplasms
1
Breast Cancer Metastatic
1
Interventions
pembrolizumab
18
Paclitaxel
13
Carboplatin
10
Pemetrexed
4
Cisplatin
4
patritumab deruxtecan
3
Gemcitabine
3
Docetaxel
3
Capecitabine
3
Albumin-Bound Paclitaxel
3
Histamine H2 Antagonists
2
Histamine Antagonists
2
Dexamethasone
2
Acetaminophen
2
130-nm albumin-bound paclitaxel
2
trastuzumab deruxtecan
1
osimertinib
1
olaparib
1
liposomal doxorubicin
1
lenvatinib
1
enzalutamide
1
cemiplimab
1
Vascular Endothelial Growth Factor A
1
Serotonin 5-HT3 Receptor Antagonists
1
Ramucirumab
1
Oxaliplatin
1
Neurokinin-1 Receptor Antagonists
1
Neoadjuvant Therapy
1
Levoleucovorin
1
Leucovorin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Recruiting
×
Parkinson Disease 4, Autosomal Dominant Lewy Body
×
patritumab deruxtecan
×
Clear all
NCT06469944
2026-05-26
MK-3475-06C
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
160 enrolled
NCT04165070
2026-05-18
MK-3475-01A
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
450 enrolled
NCT06445972
2026-05-12
MK-3475-06D
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
210 enrolled